dc.creator | Algar, Sergio | es |
dc.creator | Vázquez-Villa, Henar | es |
dc.creator | Aguilar-Garrido, Pedro | es |
dc.creator | Navarro-Aguadero, Miguel Ángel | es |
dc.creator | Velasco-Estévez, María | es |
dc.creator | Sánchez-Merino, Anabel | es |
dc.creator | Giner Arroyo, Rafael Luis | es |
dc.creator | Tamargo Azpilicueta, Joaquín | es |
dc.creator | Díaz Moreno, Irene | es |
dc.creator | Benhamú, Bellinda | es |
dc.date.accessioned | 2024-06-05T09:31:48Z | |
dc.date.available | 2024-06-05T09:31:48Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Algar, S., Vázquez-Villa, H., Aguilar-Garrido, P., Navarro-Aguadero, M.Á., Velasco-Estévez, M., Sánchez-Merino, A.,...,Benhamú, B. (2023). Cancer-Stem-Cell Phenotype-Guided Discovery of a Microbiota- Inspired Synthetic Compound Targeting NPM1 for Leukemia. JACS Au, 4 (5), 1786-1800. https://doi.org/10.1021/jacsau.3c00682. | |
dc.identifier.issn | 2691-3704 | es |
dc.identifier.uri | https://hdl.handle.net/11441/159727 | |
dc.description.abstract | The human microbiota plays an important role in human health and disease, through the secretion of metabolites that regulate key biological functions. We propose that microbiota metabolites represent an unexplored chemical space of small druglike molecules in the search of new hits for drug discovery. Here, we describe the generation of a set of complex chemotypes inspired on selected microbiota metabolites, which have been synthesized using asymmetric organocatalytic reactions. Following a primary screening in CSC models, we identified the novel compound UCM-13369 (4b) whose cytotoxicity was mediated by NPM1. This protein is one of the most frequent mutations of AML, and NPM1-mutated AML is recognized by the WHO as a distinct hematopoietic malignancy. UCM-13369 inhibits NPM1 expression, downregulates the pathway associated with mutant NPM1 C+, and specifically recognizes the C-end DNA-binding domain of NPM1 C+, avoiding the nucleus-cytoplasm translocation involved in the AML tumorological process. The new NPM1 inhibitor triggers apoptosis in AML cell lines and primary cells from AML patients and reduces tumor infiltration in a mouse model of AML with NPM1 C+ mutation. The disclosed phenotype-guided discovery of UCM-13369, a novel small molecule inspired on microbiota metabolites, confirms that CSC death induced by NPM1 inhibition represents a promising therapeutic opportunity for NPM1-mutated AML, a high-mortality disease. | es |
dc.description.sponsorship | MCIN/AEI/10.13039/501100011033 and FEDER PID2022-138797OB-I00, PGC2018-096049-B-I00 and PID2021-126663NB-I00 | es |
dc.description.sponsorship | MCIN/AEI/10.13039/501100011033 PID2019-106279RB-I00 | es |
dc.description.sponsorship | MCIN/AEI/10.13039/501100011033 and European Union (UE) PDC2022- 133488-I00 | es |
dc.description.sponsorship | Instituto de Salud Carlos III PI21/00191 and CP19/00140 | es |
dc.description.sponsorship | Junta de Andalucía BIO-198 and P18-FR-3487 | es |
dc.format | application/pdf | es |
dc.format.extent | 15 p. | es |
dc.language.iso | eng | es |
dc.publisher | AMER CHEMICAL SOC | es |
dc.relation.ispartof | JACS Au, 4 (5), 1786-1800. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Drug discovery | es |
dc.subject | Small molecule | es |
dc.subject | Microbiota | es |
dc.subject | Organocatalysis | es |
dc.subject | Stem cells | es |
dc.subject | NPM1 | es |
dc.subject | Leukemia | es |
dc.title | Cancer-Stem-Cell Phenotype-Guided Discovery of a Microbiota- Inspired Synthetic Compound Targeting NPM1 for Leukemia | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Bioquímica Vegetal y Biología Molecular | es |
dc.relation.projectID | PID2022-138797OB-I00 | es |
dc.relation.projectID | PGC2018-096049-B-I00 | es |
dc.relation.projectID | PID2021-126663NB-I00 | es |
dc.relation.projectID | PID2019-106279RB-I00 | es |
dc.relation.projectID | PDC2022- 133488-I00 | es |
dc.relation.projectID | PI21/00191 | es |
dc.relation.projectID | CP19/00140 | es |
dc.relation.projectID | BIO-198 | es |
dc.relation.projectID | P18-FR-3487 | es |
dc.relation.publisherversion | https://doi.org/10.1021/jacsau.3c00682 | es |
dc.identifier.doi | 10.1021/jacsau.3c00682 | es |
dc.journaltitle | JACS Au | es |
dc.publication.volumen | 4 | es |
dc.publication.issue | 5 | es |
dc.publication.initialPage | 1786 | es |
dc.publication.endPage | 1800 | es |
dc.contributor.funder | Ministerio de Ciencia e Innovación (MICIN). España | es |
dc.contributor.funder | Agencia Estatal de Investigación. España | es |
dc.contributor.funder | European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER) | es |
dc.contributor.funder | European Union (UE) | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |
dc.contributor.funder | Junta de Andalucía | es |